Skip to main content
. 2022 Oct 13;127:10.48101/ujms.v127.8959. doi: 10.48101/ujms.v127.8959

Figure 1.

Figure 1

(a) IgG-antibodies against coronavirus disease 2019 (COVID-19) spike protein (Anti-S) after SARS-CoV-2 BNT162b2 mRNA vaccination 7–15 weeks (AntiS1) and 6–8 months after the second vaccine dose (AntiS2), 3 weeks (AntiS3), and 3 months after the third dose (AntiS4) in the 40 patients who remained during the entire study. (b) The individual change in IgG-antibodies against COVID-19 spike protein (Anti-S) after SARS-CoV-2 BNT162b2 mRNA vaccination in 40 patients who remained during the entire study (‘spaghetti chart’). *P < 0.05, **P < 0.01, and ***P < 0.001. P-values are adjusted for False Discovery Rate (FDR).